Breaking New Ground: Reducing Treatment Burden in Neovascular AMD (CME Monograph)
By 2030, it is estimated that 3.7 million peoplein the United States will have advanced age-related macular degeneration (AMD), including neovascular AMD (nAMD) and geographic atrophy, yet current treatments for nAMD leave much to be desired in terms of efficacy, safety, and treatment burden. A growing body of research on newly approved or investigational “next-generation” therapies suggests that novel mechanisms of action may lessen treatment burden for nAMD. These include an antibody fragment, a DARPin (designed ankyrin repeat protein), a bispecific antibody, and viral gene delivery and expression. Importantly, no 2 patients are alike in their degree of disease activity and severity, leading experts to question if an individualized approach to treatment with current modalities—along with careful disease activity monitoring—is a viable approach to save vision while reducing treatment burden. This monograph, based on a roundtable discussion among 3 leading retina specialists, will review new developments and cutting-edge data on next-generation treatments and individualized, patient-centered management. A series of challenging cases will also be discussed. The desired results of this educational activity are for retina specialists and other ophthalmologists to evaluate emerging treatments, with the aim to reduce the treatment burden of nAMD while comparing their potential clinical use against the current standard of care.
This educational activity is intended for retina specialists and other ophthalmologists.
Upon completion of this activity, participants will be better able to:
- Contrast the mechanism of extended therapeutic effect for investigational and current treatments for nAMD
- Describe recent clinical trial data for approved and emerging treatments for nAMD
- Develop re-treatment plans for patients with nAMD that consider observed disease activity and treatment burden
Arshad M. Khanani, MD, MA (Chair)
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada, Reno School of Medicine
Baruch D. Kuppermann, MD, PhD
Roger F. Steinert Endowed Professor
Chair, Department of Ophthalmology
Director, Gavin Herbert Eye Institute
University of California, Irvine
Christina Y. Weng, MD, MBA
Associate Professor of Ophthalmology
Fellowship Program Director, Vitreoretinal Diseases & Surgery
Director, Medical Student Clinical Elective, Ben Taub General Hospital
Baylor College of Medicine
Disclosure Policy Statement
It is the policy of New York Eye and Ear Infirmary of Mount Sinai that the faculty and anyone in a position to control activity content disclose any real or apparent conflicts of interest relating to the topics of the educational activity in which they are participating. They are also required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations. New York Eye and Ear Infirmary of Mount Sinai is committed to providing its learners with quality CME activities and related materials that promote improvements in healthcare and not the proprietary interests of a commercial interest and, thus, has established policies and procedures in place that identify and resolve all conflicts of interest prior to the execution or release of its educational activities. Full disclosure of faculty/planners and their commercial relationships, if any, follows.
Arshad M. Khanani, MD, MA, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Adverum; Allergan; Bausch & Lomb Incorporated; Chengdu Kanghong Pharmaceutical Group Co Ltd; D.O.R.C. Dutch Ophthalmic Research Center (International) B.V.; EyePoint Pharmaceuticals; Gemini Therapeutics; Genentech, Inc; GrayBug, Inc; Gyroscope; Novartis Pharmaceuticals Corporation; Opthea; Oxurion NV; PolyPhotonix; Recens Medical; and Regenxbio Inc; Contracted Research: Adverum; Allergan; Chengdu Kanghong Pharmaceutical Group Co Ltd; Gemini Therapeutics; Genentech, Inc; GrayBug, Inc; Gyroscope; Novartis Pharmaceuticals Corporation; Opthea; Oxurion NV; PolyPhotonix; Recens Medical; and Regenxbio Inc; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Allergan; Genentech, Inc, and Novartis Pharmaceuticals Corporation.
Baruch D. Kuppermann, MD, PhD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Allegro Ophthalmics, LLC; Allergan; Aprea Therapeutics; Cell Care Therapeutics; Eyedaptic Inc; Galimedix Therapeutics, Inc; Genentech, Inc; Glaukos Corporation; Interface Biologics, Inc; IVERIC bio; jCyte; Novartis Pharmaceuticals Corporation; Oculis SA, Inc; Regeneron Pharmaceuticals, Inc; Re-Vana Therapeutics; Ripple Therapeutics; and Theravance Biopharma; Contracted Research: Alcon, Inc; Allegro Ophthalmics, LLC; Allergan; Apellis Pharmaceuticals; Genentech, Inc; GlaxoSmithKline plc; Ionis Pharmaceuticals, Inc; IVERIC bio; jCyte; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals, Inc.
Christina Y. Weng, MD, MBA, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Alcon; Alimera Sciences; Allergan; D.O.R.C. Dutch Ophthalmic Research Center (International) B.V.; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals, Inc.
New York Eye and Ear Infirmary of Mount Sinai Peer Review Disclosure
Gennady Landa, MD, has no relevant commercial relationships to disclose.
Editorial Support Disclosures
Erika Langsfeld, PhD; Cynthia Tornallyay, RD, MBA, CHCP; Barbara Aubel; and Michelle Ong have no relevant commercial relationships to disclose.
The contributing physicians listed above have attested to the following:
- that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;
- that practice recommendations given relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
- that all reasonable clinical alternatives will be discussed when making practice recommendations.
The New York Eye and Ear Infirmary of Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This educational activity was developed and implemented in collaboration with MedEdicus LLC.
AMA Credit Designation Statement
The New York Eye and Ear Infirmary of Mount Sinai designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This continuing medical education activity is supported through an unrestricted educational grant from Allergan.
This CME activity includes discussion of unlabeled and/or investigative uses of drugs. Please refer to the official prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.
New York Eye and Ear Infirmary of Mount Sinai Privacy & Confidentiality Policies
CME Provider Contact Information
For questions about this activity, call 917-270-7571.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of New York Eye and Ear Infirmary of Mount Sinai, MedEdicus LLC, Allergan, or Retina Specialist.
This CME activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 227
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation
Clicking Register indicates that you have reviewed the CME information for this activity.
Learning Method and Medium
This educational activity consists of a supplement and ten (10) study questions. The participant should, in order, read the learning objectives contained at the beginning of this supplement, read the supplement, answer all questions in the post test, and complete the Activity Evaluation/Credit Request form. To receive credit for this activity, please follow the instructions provided on the post test and Activity Evaluation/Credit Request form. This educational activity should take a maximum of 1.5 hours to complete.